National Bank of Canada FI Has $62.14 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

National Bank of Canada FI lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 97,984 shares of the biopharmaceutical company’s stock after selling 5,244 shares during the period. National Bank of Canada FI owned 0.09% of Regeneron Pharmaceuticals worth $62,142,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Brighton Jones LLC increased its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. American Assets Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $427,000. F M Investments LLC increased its holdings in shares of Regeneron Pharmaceuticals by 8.5% in the fourth quarter. F M Investments LLC now owns 7,003 shares of the biopharmaceutical company’s stock valued at $4,988,000 after purchasing an additional 550 shares in the last quarter. Phoenix Financial Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 19.0% in the fourth quarter. Phoenix Financial Ltd. now owns 2,103 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 336 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 14.5% in the fourth quarter. Kennedy Capital Management LLC now owns 5,156 shares of the biopharmaceutical company’s stock valued at $3,673,000 after purchasing an additional 652 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on REGN shares. Citigroup reaffirmed a “buy” rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research note on Monday, August 4th. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $841.30.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of REGN stock opened at $563.00 on Friday. The company has a current ratio of 4.60, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm’s fifty day moving average price is $536.80 and its two-hundred day moving average price is $599.75. The firm has a market capitalization of $60.78 billion, a P/E ratio of 14.19, a PEG ratio of 1.89 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $11.56 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.